Compare Danaher Corporation (DHR) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs iShares MSCI India ETF — how do they compare? Danaher Corporation trades at $206.55 (market cap $145.83B), while iShares MSCI India ETF trades at $49.93. The key difference: Danaher Corporation pays a 0.77% dividend while iShares MSCI India ETF pays none, and Danaher Corporation is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| DHR | INDA | |
|---|---|---|
Market Cap | $145.83B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $242.05 | $55.29 |
52-Week Low | $161.91 | $45.42 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
INDA trades at $50.04, down 0.2% with a bullish technical signal from moving averages. The ETF reflects India's economic growth at 7.8% (CNBC, 2026-06-05) but faces headwinds from foreign outflows and sector-specific challenges in pharma and IT. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while ADX indicates strong trend strength.
Outlook remains cautiously optimistic given India's strong economic fundamentals, though near-term risks include geopolitical tensions, monsoon uncertainties, and foreign capital rotation away from emerging markets. The ETF offers exposure to the world's fastest-growing large economy but requires monitoring of external pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
